ImaginAb, Inc. Announces Formation of Singapore Subsidiary, ImaginAb Molecular Imaging Pte Ltd.
LOS ANGELES and SINGAPORE, Sept. 6, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the establishment of a wholly owned Singapore-based subsidiary, ImaginAb Molecular Imaging Pte Ltd (IMI). IMI is the first step in the company's international expansion and marks a significant increase in research capability for the organization. IMI will be established to provide GLP pre-clinical molecular imaging services to both the US parent company and select biopharma partnerships, including optical imaging and positron emission tomography (PET) services.
Christian P. Behrenbruch, Ph.D, ImaginAb's CEO, commented, "Singapore has tremendous resources and facilities of interest to ImaginAb. We already have a close dialog with several A*Star Research Institutes (RIs) and a formalized collaboration with Sir David Lane's lab at the Institute of Molecular Biology (IMB)." The establishment of IMI will strengthen the possibility of further collaborations with A*Star, university labs and several global pharmaceutical companies who have established translational medicine units in Singapore.
"Establishing a significant research footprint in Singapore has been a straightforward process, greatly facilitated by the ease of working with A*Star, EDB and other government stakeholders who are committed to bringing highly innovative US companies to a growing and dynamic biotech cluster," commented Dr. Behrenbruch. "We are impressed with the quality of industry-accessible core resources and the international talent base in Singapore. We also expect ImaginAb's footprint in Singapore will also enable the company to better service a rapidly growing client base in Korea, Japan and China."
About ImaginAb, Inc.
Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
SOURCE ImaginAb, Inc.